摘要
目的探讨通心络联合规范西医治疗对缺血性心肌病(ICM)患者心肌纤维化(MF)的影响。方法将83例ICM患者随机分为2组,对照组(n=41)及通心络治疗组(n=42)。对照组采用规范的西医治疗;通心络治疗组在规范的西医治疗基础上,加用通心络治疗(每次3粒,3次/日)。随访半年,所有研究对象在初始及随访结束时两次行血清hsCRP、Ⅰ型前胶原羧基末端前肽(PIP)、血清Ⅰ型胶原羧基端交联肽(CITP)及Ⅲ型N端胶原前肽(PIIINP)水平检测。结果研究结束时,与对照组比较,通心络治疗组血清hsCRP、PIP/CITP比值及PIIINP水平明显降低,血清CITP水平明显升高,差异有统计学意义(P<0.05);血清hsCRP与PIP/CITP比值存在正相关。结论通心络可降低ICM患者MF水平。
Objective To investigate the effect of combined application of Tongxinluo and standard modern medicine treatment on myocardial fibrosis ( MF ) in patients with ischemie cardiomyopathy (ICM). Methods Eighty three patients with ICM were randomly divided into two groups: control group (n = 41 ) and Tongxinluo treatment group ( n = 42). Control group was treated with standard Western medical treatment; and Tongxinluo treatment group was given Tongxinluo (3, rid ) in addition to western medicineAfter 6 months' treatment, levels of serum hsCRP, carboxyl-terminal propeptide of procollagen type I (PIP) , carboxyl- termi- nal telopeptide of collagen type I (CITP) and amino-terminal propeptide of procollagen type III (PIIINP) were observed. Results At the end of this study, Tongxinluo treatment group manifested withsignificantly de- creased levels of serum hsCRP, PIP/CITP and PIIINP, and increased levels of serum CITP in comparison with control group ( P 〈 0.05 ). There was positive correlation between hsCRP and PIP/CITP. Conclusion Tongx- inlong might improve MF in patients with ICM.
出处
《新医学》
2013年第10期681-684,共4页
Journal of New Medicine
基金
广东省中医药管理局资助项目(20121012)
关键词
通心络
缺血性心肌病
心肌纤维化
C反应蛋白
Tongxinlong
Ischemic cardiomyopathy
Myocardial fibrosis
C reaction protein